Price in deferred time of 15 minutes
Last quote
10/23/2024 -
17:35:26
|
Bid
10/23/2024 -
20:10:31
|
Bid Volume |
Ask
10/23/2024 -
17:19:59
|
Ask Volume |
---|---|---|---|---|
78.04
+0.19
(
+0.24% )
|
77.00
|
100 |
78.16
|
195 |
Analysis date: 18.10.2024
Global Evaluation
Neutral
Neutral
The stock is classified in the neutral zone since 13.09.2024.
Interest
Strong
Strong
Strong interest since 11.10.2024.
Earnings Rev Trend
Positive
Positive
Compared to seven weeks ago, the analysts have raised their earnings per share estimates. This positive trend began 11.10.2024 at a price of 79.51.
Evaluation
Undervalued
Undervalued
Based on its growth potential and our own criteria, at its current price the stock is moderately undervalued.
MT Tech Trend
Neutral
Neutral
The stock is currently trading close to its forty day moving average (changes between +1.75% and -1.75% are considered neutral). Prior to this (since 23.08.2024), the stock traded above its moving average. The confirmed Technical Reverse point (Tech Reverse - 1.75%) is 76.917.
4wk Rel Perf
-2.65%
-2.65%
The four week relative underperformance versus STOXX600 is 2.65%.
Sensibility
Middle
Middle
The stock has been on the moderate-sensitivity level since 23.08.2024.
Bear Market Factor
Middle
Middle
On average, the stock is likely to decline with the index.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 2.09%.
Mkt Cap in $bn
21.63
21.63
With a market capitalization >$8bn, GALDERMA GROUP is considered a large-cap stock.
G/PE Ratio
1.65
1.65
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 1.6 often suggests the projected growth is a result of a base effect, meaning the company can often be in a turn around situation. In this case, the estimated PE is a better indicator of a stock's expected growth than the Long Term Growth (LT Growth).
LT P/E
23.02
23.02
The estimated PE is for the year 2026.
LT Growth
37.66%
37.66%
The annualized growth estimate is for the current year to 2026.
Avg. Nb analysts
9
9
Over the last seven weeks, an average of 9 analysts provided earnings per share estimates.
Dividend Yield
0.27%
0.27%
The twelve month estimated dividend yield represents 6.20% of earnings forecasts.
Beta
76
76
For 1% of index variation, the stock varies on average by 0.76%.
Correlation
0.23
0.23
Stock movements are strongly independent of index variations.
Value at Risk
13.78
13.78
The value at risk is estimated at CHF 13.78. The risk is therefore 17.46%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
23.08.2024
23.08.2024